Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Abstract Background Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastase...

Full description

Bibliographic Details
Main Authors: Robert Olson, Mitchell Liu, Alanah Bergman, Sonya Lam, Fred Hsu, Benjamin Mou, Tanya Berrang, Ante Mestrovic, Nick Chng, Derek Hyde, Quinn Matthews, Chad Lund, Daniel Glick, Howard Pai, Parminder Basran, Hannah Carolan, Boris Valev, Shilo Lefresene, Scott Tyldesley, Devin Schellenberg
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Cancer
Subjects:
Stereotactic ablative radiotherapy
Oligometastases
Radiotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-4859-7

Similar Items

Similar Items